AP2358A - Thiazole compounds and methods of use. - Google Patents
Thiazole compounds and methods of use.Info
- Publication number
- AP2358A AP2358A AP2007004268A AP2007004268A AP2358A AP 2358 A AP2358 A AP 2358A AP 2007004268 A AP2007004268 A AP 2007004268A AP 2007004268 A AP2007004268 A AP 2007004268A AP 2358 A AP2358 A AP 2358A
- Authority
- AP
- ARIPO
- Prior art keywords
- methods
- thiazole compounds
- thiazole
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67913305P | 2005-05-09 | 2005-05-09 | |
| PCT/US2006/017692 WO2006122011A2 (en) | 2005-05-09 | 2006-05-09 | Thiazole compounds and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AP2007004268A0 AP2007004268A0 (en) | 2007-12-31 |
| AP2358A true AP2358A (en) | 2012-01-30 |
Family
ID=36968742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AP2007004268A AP2358A (en) | 2005-05-09 | 2006-05-09 | Thiazole compounds and methods of use. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US8088806B2 (pt) |
| EP (1) | EP1879575A2 (pt) |
| JP (1) | JP2008540537A (pt) |
| KR (1) | KR20080019213A (pt) |
| CN (1) | CN101247807A (pt) |
| AP (1) | AP2358A (pt) |
| AU (1) | AU2006244203B2 (pt) |
| BR (1) | BRPI0608910A2 (pt) |
| CA (1) | CA2607617A1 (pt) |
| EA (1) | EA200702445A1 (pt) |
| IL (1) | IL186970A0 (pt) |
| MX (1) | MX2007013955A (pt) |
| NO (1) | NO20075723L (pt) |
| NZ (1) | NZ563866A (pt) |
| SG (1) | SG159561A1 (pt) |
| UA (1) | UA92746C2 (pt) |
| WO (1) | WO2006122011A2 (pt) |
| ZA (1) | ZA200709751B (pt) |
Families Citing this family (123)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2618370A1 (en) * | 2005-08-04 | 2007-02-15 | Sirtris Pharmaceuticals, Inc. | Oxazolopyridine derivatives as sirtuin modulators |
| CA2645072A1 (en) * | 2006-03-08 | 2007-09-13 | Achillion Pharmaceuticals, Inc. | Substituted aminothiazole derivatives with anti-hcv activity |
| TW200808788A (en) | 2006-04-19 | 2008-02-16 | Astellas Pharma Inc | Azolecarboxamide derivative |
| CN101096363B (zh) * | 2006-06-27 | 2011-05-11 | 中国人民解放军军事医学科学院毒物药物研究所 | 2,4,5-三取代噻唑类化合物、其制备方法、药物组合物及其制药用途 |
| CN101522623B (zh) | 2006-08-03 | 2013-06-12 | 塔夫茨大学信托人 | 无潮红烟酸类似物和其使用方法 |
| AU2007288245A1 (en) | 2006-08-24 | 2008-02-28 | Novartis Ag | 2- (pyrazin-2-yl) -thiazole and 2- (1h-pyrazol-3-yl) -thiazole derivatives as well as related compounds as stearoyl-CoA desaturase (SCD) inhibitors for the treatment of metabolic, cardiovascular and other disorders |
| JP5351025B2 (ja) | 2006-09-22 | 2013-11-27 | ノバルティス アーゲー | ヘテロ環式有機化合物 |
| TW200831084A (en) * | 2006-11-21 | 2008-08-01 | Genelabs Tech Inc | Anti-viral compounds |
| MX2009006728A (es) | 2006-12-20 | 2009-09-09 | Novartis Ag | Heterociclos de 5 miembros 2-sustituidos como inhibidores de scd. |
| US7985763B2 (en) | 2007-04-10 | 2011-07-26 | National Health Research Institutes | Hepatitis C virus inhibitors |
| WO2008128335A1 (en) * | 2007-04-20 | 2008-10-30 | Merck Frosst Canada Ltd. | Novel heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| MX2009012613A (es) * | 2007-05-22 | 2010-04-21 | Achillion Pharmaceuticals Inc | Tiazoles substituidos por heteroarilo y su uso como agentes antivirales. |
| AU2008253512A1 (en) * | 2007-05-23 | 2008-11-27 | Merck Frosst Canada Ltd. | Bicyclic heteroaromatic compounds as inhibitors of stearoyl-coenzyme A delta-9 desaturase |
| US7897764B2 (en) | 2007-06-08 | 2011-03-01 | National Health Research Institutes | Thiourea derivatives |
| CL2008001821A1 (es) | 2007-06-20 | 2009-03-13 | Sirtris Pharmaceuticals Inc | Compuestos derivados de imidazo[2,1-b]-tiazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes, sindrome metabolico, resistencia a la insulina, entre otras. |
| GB2455111A (en) * | 2007-11-28 | 2009-06-03 | Addex Pharmaceuticals Sa | Metabotropic glutamate receptor (mGluR4) modulators having 5- or 6-membered N-heteroaryl ring substituted by both N-cyclylamino & 5-membered N-heteroaryl ring |
| JP2010533147A (ja) * | 2007-07-13 | 2010-10-21 | アデックス ファルマ エス．エイ． | 代謝調節型グルタミン酸レセプターのモジュレーターとしてのピラゾール誘導体 |
| EP3173414A1 (en) | 2007-07-17 | 2017-05-31 | ACEA Biosciences Inc. | Heterocyclic compounds and uses as anticancer agents |
| AU2008280784A1 (en) * | 2007-07-20 | 2009-01-29 | Merck Frosst Canada Ltd | Bicyclic heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| CN101808995A (zh) * | 2007-07-27 | 2010-08-18 | 百时美施贵宝公司 | 新颖的葡糖激酶激活剂及其使用方法 |
| ES2550755T3 (es) * | 2007-08-03 | 2015-11-12 | Romark Laboratories, L.C. | Compuestos de tiazolida sustituidos con alquilsulfonilo |
| EP2195312B1 (en) * | 2007-10-09 | 2012-11-21 | Merck Patent GmbH | Pyridine derivatives useful as glucokinase activators |
| US8389736B2 (en) * | 2007-10-16 | 2013-03-05 | The Regents Of The University Of California | Compounds having activity in correcting mutant-CFTR processing and uses thereof |
| US8304547B2 (en) | 2007-10-24 | 2012-11-06 | Astellas Pharma Inc. | Azolecarboxamide compound or salt thereof |
| EP2070925A1 (de) | 2007-12-10 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Neue 2-substituierte Tiazol-4-carbonsäureamid-Derivative deren Herstellung und Verwendung als Arzneimittel |
| EP2070924A1 (de) | 2007-12-10 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Neue 2-Hetarylthiazol-4-carbonsäureamid-Derivative, deren Herstellung und Verwendung als Arzneimittel |
| EP2070916A1 (de) | 2007-12-10 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | 2-Aryl-thiazol-4-carbonsäureamid-Derivate, deren Herstellung und Verwendung als Arzneimittel |
| TWI361808B (en) | 2008-01-08 | 2012-04-11 | Nat Health Research Institutes | Imidazolidinone and imidazolidinethione derivatives |
| EP2101173A1 (en) | 2008-03-14 | 2009-09-16 | Vivalis | In vitro method to determine whether a drug candidate active against a target protein is active against a variant of said protein |
| US8198284B2 (en) | 2008-04-30 | 2012-06-12 | National Health Research Institutes | Treatment of neurodegenerative disorders with thiourea compounds |
| US8106209B2 (en) * | 2008-06-06 | 2012-01-31 | Achillion Pharmaceuticals, Inc. | Substituted aminothiazole prodrugs of compounds with anti-HCV activity |
| US8362050B2 (en) | 2008-06-24 | 2013-01-29 | Irm Llc | Compounds and methods for modulating G protein-coupled receptors |
| ES2605815T3 (es) * | 2008-07-01 | 2017-03-16 | Ptc Therapeutics, Inc. | Moduladores de la expresión de la proteína Bmi-1 |
| WO2010009139A2 (en) | 2008-07-14 | 2010-01-21 | Gilead Colorado, Inc. | Imidazolyl pyrimidine inhibitor compounds |
| NZ602832A (en) | 2008-07-14 | 2014-04-30 | Gilead Sciences Inc | Fused heterocyclic hdac inhibitor compounds |
| CA2728228A1 (en) | 2008-07-14 | 2010-01-21 | Gilead Sciences, Inc. | Oxindolyl inhibitor compounds |
| MX2011001090A (es) | 2008-07-28 | 2011-03-15 | Gilead Sciences Inc | Compuestos de inhibidor de desacetilasa de histona de cicloalquilideno y heterocicloalquilideno. |
| UA103195C2 (uk) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
| KR101616396B1 (ko) | 2008-08-11 | 2016-04-28 | 글락소스미스클라인 엘엘씨 | 신규의 아데닌 유도체 |
| EA201100114A1 (ru) | 2008-08-11 | 2011-10-31 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | Производные пурина для применения в лечении аллергических, воспалительных и инфекционных заболеваний |
| US9643922B2 (en) | 2008-08-18 | 2017-05-09 | Yale University | MIF modulators |
| CA2733554A1 (en) * | 2008-08-18 | 2010-02-25 | Yale University | Mif modulators |
| US9540322B2 (en) | 2008-08-18 | 2017-01-10 | Yale University | MIF modulators |
| GB0900388D0 (en) | 2009-01-12 | 2009-02-11 | Addex Pharmaceuticals Sa | New compounds |
| CN105853415A (zh) | 2009-05-12 | 2016-08-17 | 罗马克实验室有限公司 | 卤代烷基杂芳基苯甲酰胺化合物 |
| ES2463826T3 (es) | 2009-06-08 | 2014-05-29 | Gilead Sciences, Inc. | Compuestos inhibidores de HDAC de cicloalquilcarbamato benzamida anilina |
| WO2010144371A1 (en) | 2009-06-08 | 2010-12-16 | Gilead Colorado, Inc. | Alkanoylamino benzamide aniline hdac inihibitor compounds |
| CN101928283A (zh) * | 2009-06-25 | 2010-12-29 | 上海唐润医药科技有限公司 | 具有抗hcv活性的化合物及其用途 |
| MX391013B (es) | 2009-06-26 | 2025-03-21 | Romark Laboratories Lc | Compuestos y metodos para tratar influenza. |
| EA021048B1 (ru) | 2010-02-10 | 2015-03-31 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | Малеат 6-амино-2-{[(1s)-1-метилбутил]окси}-9-[5-(1-пиперидинил)пентил]-7,9-дигидро-8н-пурин-8-она |
| US8575340B2 (en) | 2010-02-10 | 2013-11-05 | Glaxosmithkline Llc | Purine derivatives and their pharmaceutical uses |
| BR112012020552A2 (pt) * | 2010-02-19 | 2016-07-19 | Acea Biosciences Inc | compostos heterocíclicos e usos como agentes anticancerígenos |
| MX2012010664A (es) | 2010-03-17 | 2013-02-07 | Taivex Therapeutics Inc | Moduladores de actividad hec1 y sus metodos. |
| WO2012037349A2 (en) * | 2010-09-17 | 2012-03-22 | Glaxosmithkline Llc | Compounds |
| WO2012037351A1 (en) * | 2010-09-17 | 2012-03-22 | Glaxosmithkline Llc | Compounds |
| WO2012075393A2 (en) * | 2010-12-02 | 2012-06-07 | President And Fellows Of Harvard College | Activators of proteasomal degradation and uses thereof |
| US8835456B1 (en) | 2011-03-18 | 2014-09-16 | Achillion Pharmaceuticals, Inc. | NS5A inhibitors useful for treating HCV |
| WO2012136111A1 (zh) * | 2011-04-02 | 2012-10-11 | 中国人民解放军军事医学科学院毒物药物研究所 | 苯丙酸化合物、其制备方法及其医药用途 |
| CA2837481A1 (en) | 2011-05-27 | 2012-12-06 | Achillion Pharmaceuticals, Inc. | Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating hcv infections |
| WO2013033037A2 (en) * | 2011-08-26 | 2013-03-07 | The Regents Of The University Of California | Novel antiprion compounds |
| JP2014528412A (ja) * | 2011-09-30 | 2014-10-27 | キネタ・インコーポレイテツド | 抗ウイルス化合物 |
| WO2013052613A1 (en) * | 2011-10-04 | 2013-04-11 | Institute For Hepatitis And Virus Research | Substituted aminothiazoles as inhibitors of cancers, including hepatocellular carcinoma, and as inhibitors of hepatitis virus replication |
| US9926309B2 (en) | 2011-10-05 | 2018-03-27 | The Board Of Trustees Of The Leland Stanford Junior University | Pi-kinase inhibitors with anti-infective activity |
| WO2013063462A2 (en) | 2011-10-26 | 2013-05-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method of treating hcv infection with a small molecule chk2 inhibitor |
| US11071736B2 (en) | 2011-11-21 | 2021-07-27 | Taivex Therapeutics Corporation | Modulators of HEC1 activity and methods therefor |
| US9290489B2 (en) | 2012-07-06 | 2016-03-22 | Duke University | Activation of TRPV4 ion channel by physical stimuli and critical role for TRPV4 in organ-specific inflammation and itch |
| WO2014026039A2 (en) * | 2012-08-09 | 2014-02-13 | Neuropore Therapies, Inc. | Aryl-and heteroaryl-substituted benzene derivatives as modulators of pi3-kinase signalling pathways |
| WO2014063168A1 (en) | 2012-10-19 | 2014-04-24 | The Broad Institute, Inc. | Heterocycle-bisamide inhibitors of scavenger receptor bl |
| WO2014063167A1 (en) * | 2012-10-19 | 2014-04-24 | The Broad Institute, Inc. | Thiazole-based inhibitors of scavenger receptor bi |
| WO2014135423A1 (en) * | 2013-03-05 | 2014-09-12 | F. Hoffmann-La Roche Ag | N-heteroaryl substituted aniline derivatives as hcv-antivirals |
| TW201534586A (zh) | 2013-06-11 | 2015-09-16 | Orion Corp | 新穎ｃｙｐ１７抑制劑／抗雄激素劑 |
| TW201506024A (zh) | 2013-07-02 | 2015-02-16 | 必治妥美雅史谷比公司 | 作為有效ｒｏｃｋ抑制劑的三環甲醯胺衍生物 |
| JP6522602B2 (ja) | 2013-07-02 | 2019-05-29 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｒｏｃｋ阻害剤としての三環式ピリド−カルボキサミド誘導体 |
| EP3052190A4 (en) * | 2013-10-01 | 2017-07-19 | New York University | Amino, amido, and heterocyclic compounds as modulators of rage activity and uses thereof |
| JP6452711B2 (ja) | 2014-02-20 | 2019-01-16 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ | ヒトインターフェロンの誘導物質としてのピロロ［３，２］ピリミジン誘導体 |
| WO2016028325A1 (en) | 2014-08-22 | 2016-02-25 | Duke University | Trpa1 and trpv4 inhibitors and methods of using the same for organ-specific inflammation and itch |
| WO2016057518A1 (en) * | 2014-10-06 | 2016-04-14 | Kineta, Inc. | Anti-viral compounds, pharmaceutical compositions, and methods of use thereof |
| JP2017533925A (ja) | 2014-11-13 | 2017-11-16 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | アレルギー性疾患又は他の炎症状態の治療に有用なアデニン誘導体 |
| US11229628B2 (en) | 2015-01-09 | 2022-01-25 | Duke University | TRPA1 and TRPV4 inhibitors and methods of using the same for organ-specific inflammation and itch |
| ES2796276T3 (es) * | 2015-02-05 | 2020-11-26 | Ab Science | Compuestos con actividad antitumoral |
| WO2016138533A2 (en) * | 2015-02-27 | 2016-09-01 | The Regents Of The University Of California | Small molecules that enable cartilage rejuvanation |
| EP3280401B1 (en) * | 2015-04-07 | 2021-08-25 | ELA Pharma Ltd | Compositions for treating and/or preventing cell or tissue necrosis specifically targeting cathepsin c and/or cela1 and/or cela3a and/or structurally related enzymes thereto |
| CA3006930A1 (en) | 2015-12-03 | 2017-06-08 | Glaxosmithkline Intellectual Property Development Limited | Cyclic purine dinucleotides as modulators of sting |
| CN105524056A (zh) * | 2016-01-05 | 2016-04-27 | 中山大学肿瘤防治中心 | 一种氨基噻唑化合物及其制备方法和应用 |
| WO2017147526A1 (en) | 2016-02-26 | 2017-08-31 | The Board Of Trustees Of The Leland Stanford Junior University | Pi-kinase inhibitors with anti-infective activity |
| PE20181884A1 (es) | 2016-04-07 | 2018-12-07 | Glaxosmithkline Ip Dev Ltd | Amidas heterociclicas utiles como moduladores de proteinas |
| ES2781474T3 (es) | 2016-04-07 | 2020-09-02 | Glaxosmithkline Ip Dev Ltd | Amidas heterocíclicas útiles como moduladores de proteínas |
| EP3439656A4 (en) | 2016-04-07 | 2020-03-11 | Duke University | DOUBLE SMALL MOLECULE INHIBITORS OF TRPV4 AND TRPA1 FOR DISINFECTION AND ANESTHESIA |
| WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| WO2017197051A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Amine-linked c3-glutarimide degronimers for target protein degradation |
| CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
| ES2989988T3 (es) | 2016-05-10 | 2024-11-28 | C4 Therapeutics Inc | Degronímeros heterorocíclicos para la degradación de proteínas diana |
| WO2018039615A1 (en) * | 2016-08-26 | 2018-03-01 | The Regents Of The University Of California | Hair follicle stem cell activation and hair growth |
| US10875861B1 (en) | 2017-05-26 | 2020-12-29 | Rutgers, The State University Of New Jersey | Therapeutic compounds |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| CN111417630B (zh) | 2017-10-05 | 2023-06-06 | 葛兰素史克知识产权开发有限公司 | 干扰素基因刺激因子(sting)的调节剂 |
| EP3692033A1 (en) | 2017-10-05 | 2020-08-12 | GlaxoSmithKline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (sting) useful in treating hiv |
| AU2018359224B2 (en) | 2017-10-30 | 2023-10-05 | Neuropore Therapies, Inc. | Substituted phenyl sulfonyl phenyl triazole thiones and uses thereof |
| WO2019164996A1 (en) | 2018-02-21 | 2019-08-29 | Southern Research Institute | 2-aminoaryl-5-aryloxazole analogs for the treatment of neurodegenerative diseases |
| BR112020020273A2 (pt) | 2018-04-03 | 2021-04-06 | Blueprint Medicines Corporation | Inibidor de ret para uso no tratamento de câncer tendo uma alteração de ret |
| GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
| US11718593B2 (en) * | 2018-05-17 | 2023-08-08 | Southern Research Institute | 2,5-aryl-thiazole analogs for the treatment of neurodegenerative diseases |
| US12030875B2 (en) | 2018-09-07 | 2024-07-09 | PIC Therapeutics, Inc. | EIF4E inhibitors and uses thereof |
| WO2020112845A1 (en) | 2018-11-27 | 2020-06-04 | Rutgers, The State University Of New Jersey | Pharmaceutical compounds and therapeutic methods |
| US12415788B2 (en) | 2019-03-21 | 2025-09-16 | The Board Of Trustees Of The Leland Stanford Junior University | PI4-kinase inhibitors and methods of using the same |
| CN114302875A (zh) | 2019-05-16 | 2022-04-08 | 斯汀塞拉股份有限公司 | 氧代吖啶基乙酸衍生物及使用方法 |
| CN114391015A (zh) | 2019-05-16 | 2022-04-22 | 斯汀塞拉股份有限公司 | 苯并[b][1,8]萘啶乙酸衍生物和使用方法 |
| GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| CN114981265B (zh) | 2019-12-18 | 2025-01-03 | Ctxt私人有限公司 | 化合物 |
| AU2021230289A1 (en) | 2020-03-03 | 2022-09-29 | PIC Therapeutics, Inc. | eIF4E inhibitors and uses thereof |
| WO2021214020A1 (en) | 2020-04-24 | 2021-10-28 | Bayer Aktiengesellschaft | Substituted aminothiazoles as dgkzeta inhibitors for immune activation |
| EP4157829A1 (en) | 2020-05-29 | 2023-04-05 | Blueprint Medicines Corporation | Solid forms of pralsetinib |
| JP2024534127A (ja) * | 2021-08-25 | 2024-09-18 | ピク セラピューティクス， インコーポレイテッド | ｅＩＦ４Ｅ阻害剤及びその使用 |
| CN118019739A (zh) | 2021-08-25 | 2024-05-10 | 皮克医疗公司 | Eif4e抑制剂及其用途 |
| WO2023111996A1 (en) | 2021-12-17 | 2023-06-22 | Reglagene Holding, Inc. | Compositions and methods of making and using small molecules in the treatment of cancer |
| CN114249702B (zh) * | 2022-01-12 | 2023-09-05 | 沈阳药科大学 | N-芳基-[2,4′-双噻唑]-2′-胺类化合物及其制备与用途 |
| US20250092032A1 (en) * | 2022-01-17 | 2025-03-20 | Centre National De La Recherche Scientifique | Deoxycytidine kinase inhibitors |
| CN116531373B (zh) * | 2022-01-26 | 2025-02-25 | 上海日馨医药科技股份有限公司 | 噻唑类化合物、其药物组合物及应用 |
| KR20250176573A (ko) | 2023-02-28 | 2025-12-19 | 레글라진, 아이엔씨. | 건강 상태의 치료를 위한 소분자 제조 및 사용을 위한 조성물 및 방법 |
| WO2025151517A1 (en) * | 2024-01-08 | 2025-07-17 | Wavebreak Therapeutics Limited | Thiazole compounds, compositions and methods of treating disorders associated with missfolding of alpha-synuclein protein |
| WO2025166015A2 (en) * | 2024-02-02 | 2025-08-07 | Photys Therapeutics, Inc. | Bifunctional abl1-binding compounds and uses thereof |
| WO2026017723A1 (en) * | 2024-07-19 | 2026-01-22 | Givaudan Sa | Organic compound |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3458526A (en) * | 1966-09-26 | 1969-07-29 | Upjohn Co | Certain 2-amino-4,5-bis(p-methoxyphenyl)thiazoles |
| WO2002094264A1 (en) * | 2001-05-23 | 2002-11-28 | Tularik Inc. | Ccr4 antagonists |
| WO2004096798A2 (fr) * | 2003-04-25 | 2004-11-11 | Sanofi-Aventis | Derives de 2-acylamino-4-phenylthiazole, leur preparation et leur application en therapeutique |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2474194A (en) * | 1941-08-30 | 1949-06-21 | American Cyanamid Co | N-heterocyclic substituted guanamines |
| US3467666A (en) * | 1966-11-07 | 1969-09-16 | Geigy Chem Corp | 2-substituted aminothiazoles |
| BE795907A (fr) * | 1972-02-25 | 1973-06-18 | Luso Farmaco Inst | 2-amino-4-arylthiazoles 5-substitues et leur preparation |
| CA1051906A (en) * | 1973-10-24 | 1979-04-03 | Shionogi And Co. | Thiazole derivatives and production thereof |
| DK150068C (da) * | 1978-06-02 | 1987-06-29 | Pfizer | Analogifremgangsmaade til fremstilling af aminothiazoler |
| JPS6339868A (ja) | 1986-08-04 | 1988-02-20 | Otsuka Pharmaceut Factory Inc | ジ低級アルキルフエノ−ル誘導体 |
| DD271258A1 (de) * | 1988-04-06 | 1989-08-30 | Univ Leipzig | Mittel zur chemotherapie von kulturpflanzenvirosen |
| DE4029771A1 (de) | 1990-09-20 | 1992-03-26 | Basf Ag | N-heteroaryl-2-nitroaniline |
| AU689972B2 (en) | 1994-11-29 | 1998-04-09 | Hisamitsu Pharmaceutical Co., Inc. | Antibacterial preparation or bactericide comprising 2-aminothiazole derivative and/or salt thereof |
| ATE227279T1 (de) | 1995-12-29 | 2002-11-15 | Boehringer Ingelheim Pharma | Phenyl thiazol derivate mit antiherpesvirus eigenschaften |
| MY128323A (en) | 1996-09-30 | 2007-01-31 | Otsuka Pharma Co Ltd | Thiazole derivatives for inhibition of cytokine production and of cell adhesion |
| WO2000006575A2 (en) | 1998-07-28 | 2000-02-10 | Smithkline Beecham Plc | Azabicyclic compounds |
| JP2002526482A (ja) * | 1998-09-18 | 2002-08-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | ｐ３８のインヒビター |
| WO2000033837A2 (en) | 1998-12-07 | 2000-06-15 | Smithkline Beecham Corporation | Myt1 kinase inhibitors |
| WO2001021160A2 (en) | 1999-09-23 | 2001-03-29 | Axxima Pharmaceuticals Aktiengesellschaft | Carboxymide and aniline derivatives as selective inhibitors of pathogens |
| TWI284639B (en) | 2000-01-24 | 2007-08-01 | Shionogi & Co | A compound having thrombopoietin receptor agonistic effect |
| JP2003525291A (ja) | 2000-03-01 | 2003-08-26 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ２，４−二置換チアゾリル誘導体 |
| AU2001249670A1 (en) | 2000-04-03 | 2001-10-15 | 3-Dimensional Pharmaceuticals, Inc. | Substituted thiazoles and the use thereof as inhibitors of plasminogen activatorinhibitor-1 |
| AU2002213466A1 (en) | 2000-10-11 | 2002-04-22 | Chemocentryx, Inc. | Compounds and methods for modulating ccr4 function |
| GB0028383D0 (en) * | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
| WO2002051410A2 (en) | 2000-12-22 | 2002-07-04 | Akzo Nobel N.V. | Phenylthiazole and thiazoline derivatives and their use as antiparasitics |
| EP1354603A1 (en) | 2000-12-26 | 2003-10-22 | Takeda Chemical Industries, Ltd. | Concomitant drugs |
| US7169931B2 (en) | 2001-01-26 | 2007-01-30 | Shionogi & Co., Ltd. | Cyclic compounds exhibiting thrombopoietin receptor agonism |
| HN2002000156A (es) * | 2001-07-06 | 2003-11-27 | Inc Agouron Pharmaceuticals | Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización. |
| MXPA04001399A (es) | 2001-08-13 | 2004-05-27 | Janssen Pharmaceutica Nv | Derivados de tiazolilo 2-amino-4,5-trisustituidos. |
| US20040198773A1 (en) | 2001-09-26 | 2004-10-07 | Barry Hart | Substituted 3-pyridyl oxazoles as c17,20 lyase inhibitors |
| US20040267017A1 (en) | 2001-09-26 | 2004-12-30 | Bierer Donald E | 3-pyridyl or 4-isoquinolinyl thiazoles as c17, 20 lyase inhibitors |
| WO2003027101A1 (en) | 2001-09-26 | 2003-04-03 | Bayer Pharmaceuticals Corporation | Substituted 3-pyridyl pyrroles and 3-pyridyl pyrazoles as c17,20 lyase inhibitors |
| US20040236110A1 (en) | 2001-09-26 | 2004-11-25 | Ladouceur Gaetan H | Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors |
| US20040209924A1 (en) | 2001-09-26 | 2004-10-21 | Barry Hart | Substituted 3-pyridyl imidazoles as c17,20 lyase inhibitors |
| EP1482940A2 (en) | 2001-10-03 | 2004-12-08 | Pharmacia Corporation | Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade |
| EP1432687A2 (en) | 2001-10-03 | 2004-06-30 | Pharmacia Corporation | Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade |
| AU2002349705A1 (en) | 2001-12-03 | 2003-06-17 | Japan Tobacco Inc. | Azole compound and medicinal use thereof |
| US6881746B2 (en) | 2001-12-03 | 2005-04-19 | Novo Nordick A/S | Glucagon antagonists/inverse agonists |
| EP1321463B1 (en) | 2001-12-21 | 2007-08-08 | Virochem Pharma Inc. | Thiazole derivatives and their use for the treatment or prevention of Flavivirus infections |
| US20030158199A1 (en) | 2002-01-25 | 2003-08-21 | Kylix, B.V. | Novel compounds for inhibition of Tie-2 |
| CA2474322A1 (en) | 2002-01-25 | 2003-07-31 | Kylix Pharmaceuticals B.V. | 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2 |
| WO2003066215A1 (en) | 2002-02-06 | 2003-08-14 | Japan Energy Corporation | Method for preparing hydrogenation purification catalyst |
| MXPA05001277A (es) | 2002-08-02 | 2005-10-06 | Ab Science | 2-(3-aminoaril)amino-4-aril-tiazoles y su uso como inhibidores del c-kit. |
| EP1539722A1 (en) * | 2002-08-07 | 2005-06-15 | F. Hoffmann-La Roche Ag | Thiazole derivatives |
| KR101078098B1 (ko) | 2003-01-14 | 2011-10-28 | 아레나 파마슈티칼스, 인크. | 대사 조절제로서의 １,２,３-삼치환된 아릴 및 헤테로아릴유도체, 및 당뇨병 및 고혈당증을 비롯한 이에 관련된장애의 예방 및 치료 |
| CA2755297A1 (en) | 2003-02-10 | 2004-08-26 | Vertex Pharmaceuticals Incorporated | Processes for the preparation of n-heteroaryl-n-aryl-amines by reacting an n-aryl carbamic acid ester with a halo-heteroaryl and analogous processes |
| CA2515215A1 (en) | 2003-02-10 | 2004-08-26 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| JP2006517577A (ja) * | 2003-02-12 | 2006-07-27 | ファイザー・インク | 抗増殖性の２−（スルホ−フェニル）−アミノチアゾール誘導体 |
| CN1747936A (zh) | 2003-02-12 | 2006-03-15 | 特兰斯泰克制药公司 | 作为治疗试剂的取代吡咯衍生物 |
| US20080025916A1 (en) | 2003-02-27 | 2008-01-31 | Ab Science | Tailored Treatment Suitable for Different Forms of Mastocytosis |
| TW200505902A (en) | 2003-03-20 | 2005-02-16 | Schering Corp | Cannabinoid receptor ligands |
| WO2004092145A1 (en) | 2003-04-15 | 2004-10-28 | Pfizer Inc. | Alpha substituted carboxylic acid as ppar modulators |
| EP1624873A2 (en) | 2003-04-28 | 2006-02-15 | AB Science | Use of tyrosine kinase inhibitors for treating cerebral ischemia |
| WO2004098612A2 (en) | 2003-05-07 | 2004-11-18 | Ab Science | Calcitriol analogs of uses thereof |
| EP1628666B1 (en) | 2003-05-14 | 2015-09-23 | NeuroGenetic Pharmaceuticals, Inc. | Compouds and uses thereof in modulating amyloid beta |
| ATE439837T1 (de) | 2003-06-03 | 2009-09-15 | Novartis Ag | 5-gliedrige heterocyclische p-38 inhibitoren |
| WO2005000309A2 (en) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
| AR045047A1 (es) | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
| DE602004013792D1 (de) | 2003-08-15 | 2008-06-26 | Ab Science | Verwendung von c-kit-inhibitoren für die behandlung von typ-2-diabetes |
| PT1670448E (pt) | 2003-09-30 | 2008-02-11 | Tibotec Pharm Ltd | Sulfonamidas inibidoras de hcv |
| EP1686949A2 (en) | 2003-11-24 | 2006-08-09 | Viropharma Incorporated | Compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases |
| AU2005209485A1 (en) | 2004-01-30 | 2005-08-11 | Ab Science | 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors |
| WO2005077368A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
| TW200538433A (en) | 2004-02-24 | 2005-12-01 | Irm Llc | Immunosuppressant compounds and compositiions |
| WO2005099673A1 (en) | 2004-04-13 | 2005-10-27 | Icagen, Inc. | Polycylic thiazoles as potassium ion channel modulators |
| EP1755592A1 (en) | 2004-04-20 | 2007-02-28 | AB Science | Use of c-kit inhibitors for treating inflammatory muscle disorders including myositis and muscular dystrophy |
| WO2005102318A1 (en) | 2004-04-20 | 2005-11-03 | Ab Science | Use of c-kit inhibitors for treating hiv related diseases |
| US20080004279A1 (en) | 2004-04-23 | 2008-01-03 | Alain Moussy | Use of C-Kit Inhibitors for Treating Plasmodium Related Diseases |
| WO2005102346A2 (en) | 2004-04-23 | 2005-11-03 | Ab Science | Use of c-kit inhibitors for treating fibrosis |
| WO2005102326A2 (en) | 2004-04-23 | 2005-11-03 | Ab Science | Use of c-kit inhibitors for treating renal diseases |
| CA2566104A1 (en) | 2004-05-18 | 2005-12-01 | Ab Science | Use of mast cells inhibitors for treating patients exposed to chemical or biological weapons |
| WO2005115385A1 (en) | 2004-05-24 | 2005-12-08 | Ab Science | Use of c-kit inhibitors for treating acne |
| WO2005115304A2 (en) | 2004-05-24 | 2005-12-08 | Ab Science | Use of c-kit inhibitors for treating fibrodysplasia |
| MX2007003377A (es) | 2004-09-23 | 2007-05-10 | Pfizer Prod Inc | Agonistas del receptor de trombopoyetina. |
| MX2007014048A (es) | 2005-05-11 | 2008-02-05 | Abbott Lab | Antagonistas del receptor vaniloide subtipo 1 (vr1) y usos de los mismos. |
| JP2009526868A (ja) | 2006-02-15 | 2009-07-23 | アボット・ラボラトリーズ | 新規なアセチル−ＣｏＡカルボキシラーゼ（ＡＣＣ）阻害薬およびこれらの糖尿病、肥満および代謝症候群における使用 |
| CA2645072A1 (en) * | 2006-03-08 | 2007-09-13 | Achillion Pharmaceuticals, Inc. | Substituted aminothiazole derivatives with anti-hcv activity |
| MX2009012613A (es) * | 2007-05-22 | 2010-04-21 | Achillion Pharmaceuticals Inc | Tiazoles substituidos por heteroarilo y su uso como agentes antivirales. |
-
2006
- 2006-05-09 KR KR1020077028496A patent/KR20080019213A/ko not_active Ceased
- 2006-05-09 EA EA200702445A patent/EA200702445A1/ru unknown
- 2006-05-09 UA UAA200713741A patent/UA92746C2/ru unknown
- 2006-05-09 NZ NZ563866A patent/NZ563866A/en not_active IP Right Cessation
- 2006-05-09 AU AU2006244203A patent/AU2006244203B2/en not_active Ceased
- 2006-05-09 US US11/431,155 patent/US8088806B2/en not_active Expired - Fee Related
- 2006-05-09 EP EP06770077A patent/EP1879575A2/en not_active Withdrawn
- 2006-05-09 JP JP2008511226A patent/JP2008540537A/ja active Pending
- 2006-05-09 BR BRPI0608910-0A patent/BRPI0608910A2/pt not_active IP Right Cessation
- 2006-05-09 CN CNA200680025066XA patent/CN101247807A/zh active Pending
- 2006-05-09 CA CA002607617A patent/CA2607617A1/en not_active Abandoned
- 2006-05-09 MX MX2007013955A patent/MX2007013955A/es not_active Application Discontinuation
- 2006-05-09 SG SG201001098-1A patent/SG159561A1/en unknown
- 2006-05-09 AP AP2007004268A patent/AP2358A/xx active
- 2006-05-09 WO PCT/US2006/017692 patent/WO2006122011A2/en not_active Ceased
-
2007
- 2007-10-28 IL IL186970A patent/IL186970A0/en unknown
- 2007-11-09 NO NO20075723A patent/NO20075723L/no not_active Application Discontinuation
- 2007-11-13 ZA ZA200709751A patent/ZA200709751B/xx unknown
-
2011
- 2011-11-30 US US13/307,761 patent/US20120108576A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3458526A (en) * | 1966-09-26 | 1969-07-29 | Upjohn Co | Certain 2-amino-4,5-bis(p-methoxyphenyl)thiazoles |
| WO2002094264A1 (en) * | 2001-05-23 | 2002-11-28 | Tularik Inc. | Ccr4 antagonists |
| WO2004096798A2 (fr) * | 2003-04-25 | 2004-11-11 | Sanofi-Aventis | Derives de 2-acylamino-4-phenylthiazole, leur preparation et leur application en therapeutique |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2006244203B2 (en) | 2012-05-03 |
| IL186970A0 (en) | 2008-02-09 |
| US20120108576A1 (en) | 2012-05-03 |
| NZ563866A (en) | 2011-03-31 |
| KR20080019213A (ko) | 2008-03-03 |
| NO20075723L (no) | 2008-02-05 |
| BRPI0608910A2 (pt) | 2010-02-17 |
| UA92746C2 (en) | 2010-12-10 |
| ZA200709751B (en) | 2008-11-26 |
| AU2006244203A1 (en) | 2006-11-16 |
| SG159561A1 (en) | 2010-03-30 |
| CA2607617A1 (en) | 2006-11-16 |
| EP1879575A2 (en) | 2008-01-23 |
| CN101247807A (zh) | 2008-08-20 |
| JP2008540537A (ja) | 2008-11-20 |
| EA200702445A1 (ru) | 2008-04-28 |
| US8088806B2 (en) | 2012-01-03 |
| AP2007004268A0 (en) | 2007-12-31 |
| MX2007013955A (es) | 2008-02-05 |
| US20070004711A1 (en) | 2007-01-04 |
| WO2006122011A3 (en) | 2007-05-03 |
| WO2006122011A2 (en) | 2006-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP2358A (en) | Thiazole compounds and methods of use. | |
| IL190207A0 (en) | Thiazoles used as fungicides | |
| SI1910348T1 (sl) | Spojine benzotiazola in azabenzotiazola, uporabne kot kinazni inhibitorji | |
| IL189627A0 (en) | Thiazole derivatives | |
| GB0718972D0 (en) | Compounds and methods of making the compounds | |
| IL185309A0 (en) | Isoqunoline compounds and methods of use thereof | |
| ZA200902189B (en) | Phenylpropionamide compounds and the use thereof | |
| GB0512940D0 (en) | Compounds and their use | |
| IL190226A0 (en) | Organometallic compounds and methods of use thereof | |
| IL185223A0 (en) | Compounds and uses thereof | |
| EP1711496A4 (en) | THIAZOLE COMPOUNDS | |
| IL183838A0 (en) | Thiazolium compounds and uses thereof | |
| ZA200710105B (en) | Thiazole derivatives and use thereof | |
| GB0520743D0 (en) | Compounds and their use | |
| DK2392335T3 (en) | Use of 24-norUDCA | |
| ZA200802480B (en) | Thiazoles used as fungicides | |
| GB0518494D0 (en) | Thiazole compounds | |
| GB0523637D0 (en) | Process and compounds | |
| ZA200804378B (en) | Iminopropene compound and use thereof | |
| ZA200710971B (en) | Elasmobranch-repelling compounds and methods of use | |
| GB0513176D0 (en) | Compounds and their use | |
| GB0521278D0 (en) | Compounds and their use | |
| GB0521272D0 (en) | Compounds and uses thereof | |
| GB0514416D0 (en) | Compounds and uses thereof | |
| GB0507211D0 (en) | Method and uses of compounds |